Theranexus (EPA:ALTHX) | WebDisclosure

PRESS RELEASE

published on 04/23/2024 at 07:30, 2 years 6 months ago

Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide
Theranexus, Diverchim, and Inserm's ARNA laboratory receive €4.7 million funding from French Government to develop autophagy activation therapy for rare neurological diseases under the PickASO project in collaboration with France 2030

Theranexus Diverchim Autophagy Activation Therapy Inserm PickASO Project
BRIEF

published on 04/18/2024 at 18:05, 2 years 6 months ago

Theranexus et BBDF annoncent des résultats positifs pour l'étude de phase 1/2 de Batten-1

Étude Clinique Maladies Rares Theranexus Maladie De Batten CLN3 Batten-1
BRIEF

published on 04/18/2024 at 18:05, 2 years 6 months ago

Theranexus and BBDF Announce Positive Results for Batten-1 Phase 1/2 Study

Clinical Study Rare Diseases Theranexus Batten-1 Batten Disease CLN3
PRESS RELEASE

published on 04/18/2024 at 18:00, 2 years 6 months ago

Theranexus et BBDF annoncent les données finales et positives de sécurité et d'efficacité de Batten-1 dans l'étude de phase 1/2
Theranexus et la Fondation BBDF annoncent des données positives sur la stabilisation des symptômes moteurs chez les patients jeunes adultes atteints de la maladie de Batten CLN3 après 18 mois de traitement

Theranexus Fondation BBDF Maladie De Batten Stabilisation Symptômes Moteurs Traitement Batten-1
PRESS RELEASE

published on 04/18/2024 at 18:00, 2 years 6 months ago

Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1
Theranexus and BBDF announce positive final results after 18-month Phase I/II trial of Batten-1 in juvenile Batten disease (CLN3) patients, showing stabilization of motor symptoms progression in young adults

Theranexus Batten-1 BBDF Juvenile Batten Disease Phase I/II Trial
PRESS RELEASE

published on 05/10/2023 at 16:59, 3 years 5 months ago

Theranexus et BBDF obtiennent l'accord de la FDA sur les critères d'efficacité de l'étude de phase 3 de Batten-1 dans la maladie de Batten CLN3

Published on 10/30/2026 at 23:35, 1 day 1 hour ago

Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 1 hour ago

Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 1 day 4 hours ago

CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 1 day 6 hours ago

Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 9 hours ago

Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

View all ACCESSWIRE

Published on 10/31/2026 at 16:35, 8 hours 51 minutes ago

SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 2 hours ago

EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 22:30, 1 day 2 hours ago

/C O R R E C T I O N - OCI Global/
Published on 10/30/2026 at 20:17, 1 day 5 hours ago

2CRSi SA: Résultats annuels 2025-2026
Published on 10/30/2026 at 20:17, 1 day 5 hours ago

2CRSi SA: 2025-2026 annual results

View all EQS

Published on 10/30/2026 at 23:00, 1 day 2 hours ago

BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 1 day 2 hours ago

Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
Published on 10/30/2026 at 20:42, 1 day 4 hours ago

TINC en PMV investeren in Storm Group (B)
Published on 10/30/2026 at 20:42, 1 day 4 hours ago

TINC and PMV invest in Storm Group (B)
Published on 10/30/2026 at 20:42, 1 day 4 hours ago

TINC and PMV invest in Storm Group (B)

View all LES ECHOS COMFI WIRE

News